Up next

Autoplay

Cariprazine: new FDA Indication for Depression (MDD) Augmentation

1 Views • 08/28/25
Share
Side Effects
Side Effects
Subscribers
0

On Dec 16, 2022: AbbVie announced that FDA has approved Cariprazine as an adjunctive therapy to antidepressants for the treatment of major depressive disorder in adults.

This video will be summarized in the following sections:
(1) Recommended dose as an adjunctive treatment for MDD.
(2) Use with hepatic & renal impairment
(3) Cariprazine CYP450 & Drug Interactions
(4) Stay mindful of cariprazine’s long half-life
(5) Two Clinical Studies supporting this FDA indication.
(6) Adverse events seen during MDD augmentation trials.

Read detailed post here:

Show more
0 Comments sort Sort By

Up next

Autoplay